PHILADELPHIA, Sept. 22, 2026 (GLOBE NEWSWIRE) —
Aardvark Therapeutics, Inc. (NASDAQ: AARD):
Grabar Law Office is investigating claims on behalf of Aardvark Therapeutics, Inc. (NASDAQ: AARD) shareholders who purchased shares on or shortly after the Company’s February 13, 2025, initial public offering (IPO) and have continued to hold their shares.
What is This Investigation About? The investigation follows the filing of a securities class action against Aardvark and certain of its officers and directors alleging violations of the federal securities laws in connection with statements concerning the safety and prospects of the Company’s lead drug candidate, ARD-101.
If you purchased Aardvark Therapeutics, Inc. (NASDAQ: AARD) shares on or shortly after the Company’s February 13, 2025 IPO, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever through a shareholder governance action. You are encouraged to visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? According to the recently filed securities complaint, Aardvark Therapeutics, Inc. (NASDAQ: AARD) IPO offering documents represented that ARD-101 had been “well-tolerated” in earlier clinical trials, had limited systemic absorption, and had demonstrated no serious adverse events. The complaint alleges that the offering documents were materially false or misleading because they failed to disclose that ARD-101 was less safe than investors had been led to believe and that its clinical, regulatory, and commercial prospects were therefore overstated.
The complaint further alleges that similar representations concerning ARD-101’s safety continued after the IPO. For example, Company representatives subsequently described ARD-101 as having a “very, very clean” safety profile and represented that its limited systemic exposure reduced the likelihood of side effects.
Then, on February 27, 2026, Aardvark announced that it was voluntarily pausing enrollment and dosing in the Phase 3 HERO trial after identifying reversible cardiac observations during safety monitoring in a healthy-volunteer study. Following the announcement, Aardvark’s stock price allegedly declined approximately 56%, closing at $5.47 per share on March 2, 2026.
Then, on May 14, 2026, Aardvark announced that the FDA had placed a full clinical hold on the investigational new drug application for ARD-101, including the Phase 3 HERO trial and its open-label extension. According to the complaint, Aardvark’s stock declined another 32.1% the following day, closing at $4.57 per share.
What Can You Do Now? If you purchased Aardvark shares at or shortly after the February 13, 2025 IPO, and continue to own those shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/aardvark-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more. #AARD $AARD #Aardvark
Beta Bionics, Inc. (NASDAQ: BBNX):
Grabar Law Office is investigating claims on behalf of shareholders of Beta Bionics, Inc. (NASDAQ: BBNX).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/bbnx-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? According to a recently filed securities fraud class action complaint, it is alleged that Beta Bionics, Inc. (NASDAQ: BBNX), through certain of its officers, made false and/or misleading statements and/or failed to disclose that: (i) the FDA had raised numerous serious issues with the iLet device itself, namely that the device was malfunctioning and dosing patients with dangerously high levels of insulin, causing hypoglycemic events; (ii) contrary to defendants’ assertions that the complaints back-filed with the FDA pursuant to the Form 483 were of no moment and entirely benign, they instead numbered in the thousands and included hundreds of life-threatening events requiring significant medical intervention; and (iii) the FDA was not satisfied with Beta Bionics’ response to the issue, as Beta Bionics had utterly failed to implement any meaningful corrective actions.
Specifically, in October 2025, Beta Bionics, Inc. (NASDAQ: BBNX), through certain of its officers, disclosed that it had received a Form 483 from the U.S. Food and Drug Administration (“FDA”) raising concerns about iLet insulin delivery device. Yet, it is alleged, Beta Bionics and certain of its offices stressed that the letter had nothing to do with the safety or efficacy of the device itself, and that the FDA had only taken issue with Beta Bionics’ interpretation of which customer complaints needed to be reported to the FDA, such that Beta Bionics would have to back-file some additional minor customer complaints in which no medical intervention was required. The underlying class action complaint further alleges that defendants assured investors that Beta Bionics was swiftly implementing the FDA’s required changes to its complaint reporting system, and accordingly that they did not “foresee any ongoing challenge with this at all.”
On January 8, 2026, after markets closed, Beta Bionics reported an unexpected miss on new iLet patient starts. According to the underlying complaint, report disclosed that facts previously reported by the Capitol Forum in December – that Beta Bionics had received over 18,000 complaints out of less than 30,000 patients and failed to investigate, report to the FDA, or take corrective action – were credible and impacted Beta Bionics’ performance. On this news, the price of Beta Bionics common stock dropped 37%, according to the complaint.
On January 30, 2026, Beta Bionics filed a Form 8-K that disclosed that the FDA had sent Beta Bionics a warning letter connected to its earlier Form 483. It is alleged that Beta Bionics conceded that the FDA’s concerns were more serious than the minor difference in reporting-rule interpretation Beta Bionics had previously acknowledged.
Then, on February 24, 2026, the FDA allegedly released the warning letter to the public that allegedly contradicted Beta Bionics’ prior disclosure of the FDA’s concerns – and the underlying issues with iLet – making clear that any malfunction that could be life threatening must be reported to the FDA. The complaint further alleges the warning letter elaborated that any hypoglycemia requiring medical intervention was reportable because any such episode, even if resolved by giving a patient candy, raises the chances of future hypoglycemic episodes, likely more severe than the first and potentially leading to irreversible side effects, including death. On this news, the price of Beta Bionics stock declined further, according to the complaint.
What Can You Do Now? If you purchased Beta Bionics, Inc. (NASDAQ: BBNX) shares prior to July 30, 2025, and still hold shares today, you are encouraged to https://grabarlaw.com/the-latest/bbnx-shareholder-investigation/ contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #BBNX $BBNX #BetaBionics
PROCEPT BioRobotics Corporation (NASDAQ: PRCT):
Grabar Law Office is investigating claims on behalf of shareholders of PROCEPT BioRobotics Corporation (NASDAQ: PRCT).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. Please visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085.
What is Alleged? As alleged in a recently filed securities fraud class action PROCEPT BioRobotics Corporation (NASDAQ: PRCT), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts including: (i) that Procept had utilized an extensive discount program designed to incentivize its customers to place bulk orders in excess of procedure demand; (ii) that Procept’s undisclosed discount program had artificially and unsustainably inflated Procept’s reported U.S. handpiece unit sales and revenues by pulling forward sales at the expense of future periods; (iii) that Procept’s undisclosed discount program had caused customer handpiece orders to materially exceed underlying procedure demand throughout the Class Period and that this differential had materially grown over time; (iv) that Procept’s consistent surplus of U.S. handpiece unit sales relative to performed procedures had created a glut of field inventory and overstocking amongst Procept’s customer base, amounting to more than 10,000 excess units by the end of the Class Period; (v) that, as a result of (i)-(iv) above, defendants’ representations regarding Procept’s handpiece unit sales and the utilization of Procept’s field Systems were materially overstated; (vi) that, as a result of (i)-(v) above, Procept was acutely exposed to material undisclosed risks of significant operational and financial harm; and (vii) that, as a result of (i)-(vi) above, Procept was unable to achieve its stated 2025 handpiece sales and revenue guidance and such guidance lacked a reasonably achievable factual basis.
What Can You Do Now? If you purchased PROCEPT BioRobotics Corporation (NASDAQ: PRCT) shares before February 28, 2024, and still hold shares today, you are encouraged to visit https://grabarlaw.com/the-latest/procept-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #Procept #PRCT $PRCT
The Simply Good Foods Company (NASDAQ: SMPL):
Grabar Law Office is investigating claims on behalf of shareholders of The Simply Good Foods Company (NASDAQ: SMPL).
What is This Investigation About? The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.
If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, you can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. You are encouraged to visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085 to learn more.
What is Alleged? As alleged in a recently filed securities fraud class action Complaint, The Simply Good Foods Company (NASDAQ: SMPL), through certain of its officers, made materially false and misleading statements and/or failed to disclose materially adverse facts pertaining to the Company’s business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) that Simply Good Foods had lost key managerial personnel following the acquisition of OWYN necessary for the successful integration of the acquired OWYN assets; (2) that Simply Good Foods had materially increased its general and administrative spending to compensate for the loss of key managerial personnel; (3) the addition of a new pea protein supplier for OWYN prior to the acquisition had created significant product quality issues which had negatively impacted the product; (4) Simply Good Foods had engaged in promotional activities for OWYN products above its historical practices, eroding margins; (5) that, in order to stem the margin erosion, Simply Good Foods had cut brand support and marketing, further depressing product sales; (6) as a result of the above, the OWYN acquisition had largely failed to achieve its key strategic goals, the integration of OWYN had run into severe operational and execution problems, and the business and operational results for the OWYN segment had been materially negatively impacted, undermining the acquisitions economic rationale; and (7) that, as a result of the foregoing, Defendants’ positive statements about the Company’s business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
What Can You Do Now? If you purchased The Simply Good Foods Company (NASDAQ: SMPL) shares before February 24, 2024, and still hold shares today, please visit https://grabarlaw.com/the-latest/smpl-shareholder-investigation/, contact Joshua Grabar at jgrabar@grabarlaw.com, or call 267-507-6085. You can seek corporate reforms, the return of funds back to the company, and a court approved incentive award at no cost to you whatsoever. #SMPL #SimplyGoodFoods $SMPL
Attorney Advertising Disclaimer
Contact:
Joshua H. Grabar, Esq.
Grabar Law Office
One Liberty Place
1650 Market Street, Suite 3600
Philadelphia, PA 19103
Tel: 267-507-6085
Email: jgrabar@grabarlaw.com
